Richard Soll's Biography

Richard Soll, Senior Vice President, WuxiAppTec

Dr. Richard M Soll is currently Senior Vice President, Integrated Services at WuXi AppTec. In this capacity, Dr. Soll has advanced numerous programs across major target classes and therapeutic indications from hits to clinical candidates on behalf of its customers in pharma and biotech. Previously he was the Chief Scientific Officer and Vice President, R&D at the San Diego based company TargeGen where he led innovative clinical-stage drug discovery and development programs for isoform-specific PI3K inhibitors as therapeutics for inflammation, respiratory disease and cancer, mutitargeted src/VEGF inhibitors as the first topical kinase inhibitors for age-related macular degeneration and highly selective JAK2 inhibitors for the treatment of myeloproliferative disorders, ultimately culminating in the acquisition of TargeGen by Sanofi based on early clinical performance of the JAK2 inhibitor. Dr. Soll was the Vice President of Chemistry at Ontogen and also founded the chemistry department at 3-Dimensional Pharmaceuticals where he served as Vice President, Chemistry.

Dr. Soll’s drug discovery and development experiences span numerous clinical indications and cover a wide range of molecular targets including inhibitors of kinases, serine proteases, GPCRs and protein-protein interactions. Through his contributions more than 8 clinical compounds have entered the clinic for cardiovascular disease, cancer, ocular indications, and infectious diseases.

Dr. Soll has extensively published in peer reviewed journals and is an inventor of numerous issued and pending patents.